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Abstract
In this prospective, multicentre cohort study, we analysed specific prognostic factors and the impact of timing of highly active antiretro-
viral therapy (HAART) on disease progression and death among 625 human immunodeficiency virus (HIV)-1-infected, treatment-naı¨ve
patients diagnosed with an AIDS-defining disease. HAART was classified as early (<30 days) or late (30–270 days). Deferring HAART
was significantly associated with faster progression to a new AIDS-defining event/death overall (p 0.009) and in patients with Pneumocys-
tis jiroveci pneumonia (p 0.017). In the multivariate analysis, deferring HAART was associated with a higher risk of a new AIDS-defining
event/death (p 0.002; hazard ratio 1.83; 95% CI 1.25–2.68). Other independent risk factors for poorer outcome were baseline diagnosis
of AIDS-defining lymphoma, age >35 years, and low CD4+ count (<50 cells/lL).
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Introduction
Although highly active antiretroviral therapy (HAART) has
led to good control of human immunodeficiency virus (HIV)
infection in developed countries, and considerably improved
the quality of life and life-expectancy among infected individu-
als (1,2), a considerable proportion of patients continue
to be diagnosed with HIV infection at the same time as
they are diagnosed with a category C AIDS-defining dis-
ease (3–10). The optimal time for starting HAART in
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antiretroviral-naı¨ve patients with AIDS-defining opportunistic
infections (OIs) was recently addressed in randomized clinical
trials (11–15) conducted mainly in the USA, sub-Saharan
Africa, and Southeast Asia, where healthcare systems and
access to HAART are not the same as in western European
countries such as Spain. In addition, observational studies
could provide useful information on patients attended by phy-
sicians in daily clinical practice but who are not candidates for
clinical trials. We performed a prospective cohort study in
order to compare the outcome of antiretroviral-naı¨ve, HIV-1-
infected individuals with AIDS-defining OIs or neoplasms start-
ing HAART early (<30 days after HIV infection diagnosis) or
late (30–270 days after HIV infection diagnosis). We also iden-
tified prognostic factors for progression to AIDS and death.
Materials and Methods
We included all HIV-1-infected treatment-naı¨ve adults
enrolled in the PISCIS Cohort who were first diagnosed with
AIDS between January 1998 and December 2006 and who
had a CD4+ T-cell count available at diagnosis (Fig. 1). The
PISCIS Cohort is an ongoing observational study that has
included all newly attending HIV-infected patients aged
‡16 years from nine hospitals in Catalonia and one in the
Balearic Islands (Spain) since January 1998. The methodology
applied in the cohort has been described elsewhere (16–18).
Initiation of HAART was defined as the date on which an
individual initiated treatment with three or more antiretrovi-
ral drugs. The threshold of 30 days between AIDS diagnosis
and HAART was selected in order to mimic the design of clin-
ical trials on the best time to start HAART in HIV-infected
patients diagnosed with OIs (11,13). The time for starting
HAART was decided on an individual basis by treating physi-
cians based on their experience, and outcome was analysed
a posteriori. Reasons for starting HAART earlier or later were
not reported. For each individual, follow-up ended at the com-
bined endpoint of new AIDS or death (AIDS/death), namely,
12 months after the AIDS-defining event or at the date of the
last visit before 12 months of follow-up had been completed.
A new AIDS diagnosis in the first 30 days after diagnosis
of the first OI and death were not considered to be end-
points in patients not taking HAART. Patients who experi-
enced a new AIDS event or died before the initiation of
HAART during the interval of 30–270 days were included in
the deferred HAART group.
Selected patients were classified according to their first
AIDS diagnosis into five groups: tuberculosis (TB), Kaposi
sarcoma (KS), non-Hodgkin lymphoma (NHL), Pneumocystis
jiroveci pneumonia (PCP), and ‘other OIs’. Patients with a first
diagnosis of HIV encephalopathy, interstitial lymphoid pneu-
monia or HIV-associated wasting syndrome were excluded
from the analysis. Patients with a follow-up of <30 days were
n = 1754 
First AIDS diagnosis 
n = 782 
Previous treatment 
n = 972 
AIDS and naïve 
n = 625 
Patients included 
in the analysis 
n = 108 
Neither early nor deferred
HAART
n = 7079 
No AIDS diagnosis 
n = 733 
AIDS eligible, naïve, and 
available CD4 
n = 855 
AIDS eligible and naïve 
n = 122 
CD4 not available at 
baseline 
n = 117 
Follow-up<30
N = 8833 
PISCIS Cohort
FIG. 1. Flow chart of exclusion from the study population. Of the
117 patients excluded because follow-up was <30 days, 35 were lost
to follow-up and 82 presented with AIDS and/or died (43 presented
with AIDS, 36 died and three presented with AIDS and died during
the 30-day period). The 108 patients excluded because they did not
meet the criteria for assignment to the early or late group were dis-
tributed as follows: three patients presented with AIDS or died dur-
ing the late period (30–270 days) but started highly active
antiretroviral therapy (HAART) after day 270; five patients pre-
sented with AIDS or died during days 270–365; 82 patients who did
not present with an event during follow-up did not start HAART or
started after day 270; and 18 patients started other antiretroviral
treatments not classified as HAART.
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also excluded, because they were considered to be lost to
follow-up.
Survival was analysed by computing the cumulative inci-
dence of the combined endpoint (progression to AIDS/
death) with Kaplan–Meier plots. Risk factors for the com-
bined endpoint were identified with Cox regression. Two
sensitivity analyses were performed: one in which death was
considered as a single endpoint, and another in which
patients who died within 30 days of the first AIDS diagnosis
were randomly assigned to the early or late HAART groups.
All analyses were conducted with SAS 9.1. Graphics were
generated with GraphPad Prism 5.0 software.
TABLE 1. Clinical and epidemio-
logical characteristics at baseline
and outcome (n = 625)
Early HAART,
n = 277 (44.3%)
Deferred HAART,
n = 348 (55.7%)
Total,
n = 625 (100%) p
Gender (male)a 229 (82.7) 276 (79.3) 505 (80.8) 0.338
Age (years)a
<35 83 (30.0) 102 (29.3) 185 (29.6) 0.942
35–55 166 (59.9) 208 (59.8) 374 (59.8)
>55 28 (10.1) 38 (10.9) 66 (10.6)
Transmission groupa 0.024
Injecting drug users 65 (23.5) 111 (31.9) 176 (28.2)
Homosexual or bisexual 78 (28.2) 83 (23.6) 161 (25.8)
Heterosexual 115 (42.5) 143 (41.1) 258 (41.3)
Others 19 (6.9) 11 (3.2) 30 (4.8)
HIV-1 RNAa (copies/mL) (n = 592)
>100 000 182 (69.5) 247 (74.9) 429 (72.6) 0.173
HIV-1 RNA (log)b (copies/mL) (n = 592) 5.3 (4.9–5.7) 5.4 (5.0–5.7) 5.4 (5.0–5.7) 0.321
CD4+a (cells/lL)
<50 156 (56.3) 162 (46.6) 318 (50.9) 0.135
51–100 40 (14.4) 63 (18.1) 103 (16.5)
101–200 46 (16.6) 68 (20.0) 114 (18.2)
201–350 23 (8.3) 30 (8.6) 53 (8.5)
>350 12 (4.3) 25 (7.2) 37 (5.9)
CD4+b (cells/lL) 39 (15–118) 56 (22–150) 48 (18–138) 0.007
HCVa (n = 515) 65 (26.4) 99 (36.8) 164 (31.8) 0.014
AIDS-defining conditiona <0.001
TB 41 (14.8) 109 (31.2) 150 (24.0)
KS 37 (13.4) 30 (8.6) 67 (10.7)
NHL 15 (5.4) 16 (4.6) 31 (5.0)
PCP 94 (33.9) 101 (29.0) 195 (31.2)
Other OIsc 90 (32.5) 92 (26.4) 182 (29.1)
Interval between OI and HAART (days) (IQR) 12 (1–23) 60.5 (43.5–88) 34 (14–63) <0.001
TB 3 (3–21) 68 (51–109) 55 (25–84)
PCP 13 (3–25) 49 (38–67.5) 29.5 (13–49)
Other OIs 11.5 (3–22) 59 (44–95.0) 28.5 (10.5–58.5)
KS 11 (3–23) 56 (44–102) 25 (10–54)
NHL 11 (3–26) 58 (39–99) 31.5 (11–58)
HAART combinationsa 0.109
1 or 2 PIs + 2 NRTIs 165 (59.6) 162 (51.3) 327 (55.1)
2 NRTIs + 1 NNRTI 98 (35.4) 131 (41.5) 229 (38.6)
3 NNRTIs and others 14 (5.1) 23 (7.3) 37 (6.2)
Period of HAARTa 0.747
1998–2001 142 (51.3) 184 (52.9) 326 (52.2)
2002–2006 135 (48.7) 164 (47.1) 299 (47.8)
Months of follow-upb 12.0 (11.5–12.0) 12.0 (6.1–12.0) 12.0 (8.0–12.0) NA
Disease progressiona
Overall AIDS-defining events
AIDS 23 (8.3) 37 (10.3) 60 (9.6) 0.326
Death 21 (7.6) 52 (14.9) 73 (11.7) 0.004
AIDS/deathd 41 (14.8) 82 (23.6) 123 (19.7) 0.006
PCPe 15/94 (16.0) 31/101 (30.7) 46/195 (23.6) 0.015
TBe 3/41 (7.3) 20/109 (18.4) 23/150 (15.3) 0.052
Other OIse 13/90 (14.4) 23/92 (25.0) 36/182 (19.8) 0.074
KSe 5/37 (13.5) 3/30 (10.0) 8/67 (11.9) 0.380
NHLe 6/15 (40.0) 5/16 (31.3) 11/31 (35.4) 0.610
HAART, highly active antiretroviral therapy; HCV, hepatitis C virus; IQR, interquartile range; KS, Kaposi sarcoma;
NA, not applicable; NHL, non-Hodgkin lymphoma; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI,
nucleoside reverse transcriptase inhibitor; OI, opportunistic infection; PCP, Pneumocystis jiroveci pneumonia; PI, prote-
ase inhibitor; TB, tuberculosis.
an (%).
bMedian (IQR).
cOesophageal candidiasis, n = 50 (24 early arm (EA), 26 deferred arm (DA)); encephalic toxoplasmosis, n = 41 (17
EA, 24 DA); Progressive multifocal leukoencephalopathy, n = 20 (15 EA, five DA); extrapulmonary cryptococcosis,
n = 16 (eight EA, eight DA); chronic diarrhoea (Isospora belli/Cryptosporidium parvum), n = 15 (seven EA, eight DA);
Mycobacterium avium-complex disease/other mycobacterial diseases, n = 12 (eight EA, five DA); Salmonella septicae-
mia, n = 10 (one EA, nine DA); cytomegalovirus disease, n = 9 (five EA, four DA); chronic Herpes simplex infection,
n = 8 (five EA, three DA); disseminated histoplasmosis, one DA.
dFor the combined endpoint AIDS/death, only the first event for a single patient is computed; consequently, the
result of the sum of rows and columns may be different for this variable.
eOnly the combined endpoint progression to AIDS/death is reported. For these conditions, no differences in individ-
ual endpoints were observed.
Statistically significant p-values are typed in bold.
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Results
Of the 8833 patients included in the PISCIS Cohort from Janu-
ary 1998 to December 2006, 625 HIV-infected, antiretroviral-
naı¨ve individuals were eligible for the analysis (Fig. 1). The clini-
cal characteristics and outcome are described in Table 1.
Baseline clinical and demographic characteristics were
broadly similar for patients starting HAART early or late
(Table 1) and for each AIDS-defining condition analysed sep-
arately (data not shown). In a crude analysis, patients starting
HAART in the late arm had significantly higher mortality than
patients starting HAART in the early arm (p 0.004). A sub-
analysis of each AIDS-defining condition was also performed
(see Materials and Methods and Tables 1 and 2).
Patients with PCP at baseline (median CD4+ T-cell count,
28 cells/lL IQR, (12–53 cells/lL)) showed a significant advan-
tage of starting HAART early, as mortality (2.1% in early
starters and 15.8% in late starters, p <0.001) and progression
to AIDS/death (16% vs. 30.7%, p 0.015) were significantly
reduced in a crude analysis (Table 2).
For patients diagnosed with TB at baseline, the median
(IQR) CD4+ T-cell count was 98 cells/lL (29–183 cells/lL),
the most common HAART regimen was based on non-nucle-
oside reverse transcriptase inhibitors, and patients starting
HAART after 30 days from diagnosis were more likely to
achieve the combined endpoint AIDS/death than patients
starting early (p 0.052). In late starters, a trend towards
greater mortality was also observed (p 0.077). Patients with
pulmonary TB starting HAART late had a trend towards
higher mortality (p 0.066), whereas those with the extrapul-
monary forms had similar mortality rates to those of patients
starting HAART early or late (p 0.29).
When OIs other than PCP and TB were analysed globally,
patients showed a median CD4+ T-cell count of 45 (17–
127 cells/lL), and those who started HAART late had a
greater probability of disease progression (p 0.041) and a
trend towards a greater achievement of the combined end-
point AIDS/death (p 0.074).
For AIDS-related neoplasms (KS and NHL), the median
CD4+ T-cell counts were 146 cells/lL (48–277 cells/lL) and
120 cells/lL (40–254 cells/lL), respectively; no association
TABLE 2. Risk factors for AIDS/death; univariate and multivariate Cox regression models
n AIDS/death
Univariate Multivariate
HR 95% CI p HR 95% CI p
Treatment
Immediate 277 41 1 – – 1 – –
Deferred 348 82 1.64 1.13–2.39 0.0097 1.83 1.25–2.68 0.0020
OI*
Tuberculosis 150 24 1 – – 1 – –
Kaposi sarcoma 67 7 0.69 0.30–1.61 0.3892 0.79 0.34–1.85 0.5826
Non-Hodgkin lymphoma 31 12 2.51 1.22–5.14 0.0122 2.41 1.15–5.04 0.0199
Pneumocystis jiroveci pneumonia 195 48 1.66 1.00–2.74 0.0474 1.54 0.91–2.63 0.1102
Others 182 36 1.32 0.79–2.24 0.2927 1.36 0.79–2.32 0.2686
Gender
Male 505 110 1 – – 1 – –
Female 120 17 0.66 0.40–1.11 0.1170 0.65 0.38–1.09 0.0997
Age (years)
<35 185 25 1 – – 1 – –
35–55 374 79 1.74 1.10–2.77 0.0194 1.62 1.01–2.58 0.0455
>55 66 23 2.94 1.64–5.028 0.0003 2.31 1.26–4.22 0.0065
Transmission group
Injecting drug user 176 36 1 – – – – –
Non-injecting drug user 449 91 1.04 0.70–1.55 0.8352 – – –
HIV-1 RNA
£100 000 163 29 1 – – – – –
>100 000 429 93 1.21 0.79–1.83 0.3835 – – –
CD4+ (cells/lL)
<50 318 79 1 – – 1 – –
‡50 307 44 0.55 0.38–0.79 0.0014 0.62 0.42–0.92 0.0181
HCV
Negative 351 58 1 – – – – –
Positive 164 18 0.64 0.38–1.10 0.1008 – – –
Period of HAART
1998–2001 326 76 1 – – 1 – –
2002–2006 299 51 0.76 0.53–1.09 0.1322 0.70 0.49–1.01 0.0550
HAART combinations
1 or 2 PIs + 2 NRTIs 327 54 1 – – – – –
2 NRTIs + 1 NNRTI 229 37 0.99 0.65–1.52 0.9683 – – –
3 NNRTIs and others 37 4 0.64 0.23–1.78 0.7314 – – –
HAART, highly active antiretroviral therapy; HCV, hepatitis C virus; HR, hazard ratio; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse trans-
criptase inhibitor; OI, opportunistic infection; PI, protease inhibitor.
Statistically significant p-values are typed in bold.
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was found between timing of HAART and clinical progres-
sion and death.
Figs 2 and S1 show Kaplan–Meier plots of the cumulative
incidence of the combined endpoint (progression to AIDS/
death) overall, for PCP and TB only, and for ‘other OIs’. A
greater risk of clinical progression/death was observed over-
all and for people diagnosed with PCP at baseline if HAART
was started after 30 days; however, a trend was only
observed for patients with TB or other OIs at baseline.
Table 2 shows the results of univariate and multivariate
Cox regression analyses for risk factors associated with pro-
gression to AIDS and/or death; the univariate analysis
showed that patients starting HAART late had a significantly
greater risk of progressing to AIDS or dying, and this associa-
tion was even more significant after adjustment for other risk
factors (hazard ratio (HR) 1.83; 95% CI 1.25–2.68; p 0.002).
Immunological and virological responses to antiretroviral
treatment did not differ significantly between patients start-
ing HAART early or late (Table S2).
Seventy-three patients (11.7%) died and 60 (9.7%) were
diagnosed with a new AIDS event during follow-up; the
causes of death and new AIDS diagnoses are shown in
Table S1. It is of note that almost half of the deaths were
directly related to AIDS. In most cases, the reason for never
starting or delaying HAART was loss to follow-up, especially
in immigrants and active injecting drug users.
No differences in the estimates for deferring HAART
were observed between the two sensitivity analyses.
Discussion
In western countries, the frequency of diagnosis of an
AIDS-defining event at or soon after HIV diagnosis
remains high, despite efforts aimed at earlier testing and
access to care (6,7,19). Although late presentation of HIV
infection is relatively common in developed countries, only
ACTG A5164 has analysed the optimal timing of HAART
in patients with an AIDS-defining condition (excluding TB)
in this clinical setting (11). The trial concluded that, over-
all, early initiation of HAART significantly reduced the risk
of disease progression and death as compared with late
initiation of HAART. Our findings confirmed that, in Eur-
ope, late initiation of HAART is independently associated
with poorer outcome (multivariate analysis of risk factors)
and with faster progression to AIDS/death (survival analy-
sis). PCP is the most frequent OI in late presenters in
western countries. Severe pulmonary involvement is often
the cause of admission to intensive-care units, and in this
clinical setting initiation of HAART is often delayed. In our
cohort and in ACTG A5164, progression to AIDS/death
was slower for early starters (Table 1; Fig. S1a).
TB is the second most common OI in some European set-
tings and the most common OI worldwide. Almost all ran-
domized clinical trials on timing of HAART in the context of
HIV–TB co-infection have been conducted in resource-lim-
ited settings, whereas in western countries only observa-
tional data are available (20). The SAPIT, CAMELIA and
STRIDE trials demonstrated, in a resource-limited setting, a
better outcome for early starters (up to 15 days after TB
diagnosis) with a low CD4+ count (<50 cells/mm3). For TB
meningitis the benefit of early HAART was not demon-
strated (21). Our data were collected in a different clinical
setting (Spain), with an estimated mortality rate for TB of
<1/100 000 (22). We observed a trend towards lower mor-
tality (4.9% in early starters vs. 13.8% in late starters,
p 0.077) and slower progression to AIDS/death (p 0.104,
log-rank test; Fig. S1b) in HIV-infected patients with TB start-
ing HAART earlier. The category ‘other OIs’ was considered
globally, because the small number of cases prevented indi-
vidual diseases from being considered as independent catego-
ries. However, early initiation of HAART was associated
with better outcome in terms of progression to AIDS but
not in terms of mortality. Therefore, specific recommenda-
tions cannot be made for the category ‘other OIs’, owing to
the heterogeneous nature of this group (oesophageal
candidiasis, encephalic toxoplasmosis, progressive multifocal
leukoencephalopathy, extrapulmonary cryptococcosis, cyto-
megalovirus disease, and other less frequent conditions).
For AIDS-related neoplasms (KS and NHL), no advantages
were observed for starting HAART earlier or later, although
the sample size does not allow us to draw conclusions on
the best timing of HAART in these conditions. However,
HAART combined with specific therapy is crucial to improve
FIG. 2.Overall cumulative incidence of AIDS/death in antiretroviral-
naı¨ve patients presenting with an AIDS-defining disease (N = 625).
p-Values after comparison between the early and deferred highly
active antiretroviral therapy (HAART) groups: log-rank test.
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the prognosis, although no controlled data are available on
the optimal time for initiation of HAART.
One of the main reasons for delaying HAART is the possi-
bility of developing immune reconstitution inflammatory syn-
drome (IRIS), especially in very immunosuppressed patients.
In our study, data on IRIS were not collected, although we
did observe that mortality was no greater in patients starting
HAART during the first 30 days. We can therefore conclude
that, in our clinical setting, the fear of IRIS should not be an
obstacle to the early initiation of HAART.
Our study has several limitations. First, a confounding bias
could have resulted from the clinical decision to start HAART
earlier or later. Second, patients not taking HAART who died
within the first 30 days were excluded from the analysis, and
conclusions are limited for patients surviving beyond this point.
Third, the number of patients with OIs such as cryptococcosis,
encephalic toxoplasmosis, cytomegalovirus disease and AIDS-
related neoplasms is low, thus preventing us from making rec-
ommendations on the timing of HAART. Finally, IRIS episodes
were not collected, and some of the new OIs diagnosed during
the first 3 months of HAART were probably ‘unmasked’ cases
of IRIS rather than newly acquired infections.
In conclusion, patients starting HAART within the first
30 days of their AIDS diagnosis in the PISCIS Cohort are less
likely to progress to AIDS and death than patients starting
later. For PCP, we obtained similar results to those of the
ACTG study (11). Patients with TB starting HAART earlier
tended to have a better outcome, especially if they had pulmo-
nary TB. For other OIs, initiating HAART early was considered
to be an advantage, even though the sample size did not permit
a specific subanalysis for different OIs. More controlled data
are needed before the results from clinical trials on TB and
non-PCP OIs conducted in resource-limited countries (12–
15,21,23) can be extrapolated to western countries.
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(iii) Other OIs (N = 182). p values after comparison between
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